FAPI PET Positivity in Fibrolamellar Hepatocellular Carcinoma
- 17 April 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (7) , e332-e333
Abstract
Fibrolamellar hepatocellular carcinoma (HCC) is a variant of HCC. It is a malignant tumor, but its imaging features often overlap focal nodular hyperplasia, which is a benign entity. FDG PET/CT is also not much help in these cases because both lesions do not concentrate FDG. We present one such case of fibrolamellar HCC with FAPI PET/CT positivity.Keywords
This publication has 7 references indexed in Scilit:
- Comparison of the Detection Performance Between FAP and FDG PET/CT in Various CancersClinical Nuclear Medicine, 2022
- Primary Solitary Tuberculosis in the Hepatic Round Ligament Detected by 68Ga-FAPI PET/CTClinical Nuclear Medicine, 2022
- Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CTClinical Nuclear Medicine, 2022
- Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and ManagementFrontiers in Oncology, 2021
- 68Ga-DOTA-FAPI-04 PET/CT in Neuroendocrine Carcinoma of the Liver With Elevated AFP LevelClinical Nuclear Medicine, 2021
- FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular backgroundJapanese Journal of Radiology, 2020
- From the Archives of the AFIPRadioGraphics, 1999